183 related articles for article (PubMed ID: 24598047)
1. Therapeutic efficacy of p53 restoration in Mdm2-overexpressing tumors.
Li Q; Zhang Y; El-Naggar AK; Xiong S; Yang P; Jackson JG; Chau G; Lozano G
Mol Cancer Res; 2014 Jun; 12(6):901-11. PubMed ID: 24598047
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers.
Gudikote JP; Cascone T; Poteete A; Sitthideatphaiboon P; Wu Q; Morikawa N; Zhang F; Peng S; Tong P; Li L; Shen L; Nilsson M; Jones P; Sulman EP; Wang J; Bourdon JC; Johnson FM; Heymach JV
J Biol Chem; 2021 Nov; 297(5):101163. PubMed ID: 34481841
[TBL] [Abstract][Full Text] [Related]
3. Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53.
Senturk JC; Bohlman S; Manfredi JJ
Oncogene; 2017 Nov; 36(44):6085-6096. PubMed ID: 28692049
[TBL] [Abstract][Full Text] [Related]
4. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth.
Swaroop M; Sun Y
Anticancer Res; 2003; 23(4):3167-74. PubMed ID: 12926050
[TBL] [Abstract][Full Text] [Related]
5. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
6. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
7. Mdm2 overexpression and p73 loss exacerbate genomic instability and dampen apoptosis, resulting in B-cell lymphoma.
Riley MF; You MJ; Multani AS; Lozano G
Oncogene; 2016 Jan; 35(3):358-65. PubMed ID: 25915849
[TBL] [Abstract][Full Text] [Related]
8. The MDM2-a splice variant of MDM2 alters transformation in vitro and the tumor spectrum in both Arf- and p53-null models of tumorigenesis.
Volk EL; Fan L; Schuster K; Rehg JE; Harris LC
Mol Cancer Res; 2009 Jun; 7(6):863-9. PubMed ID: 19491200
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas.
Verreault M; Schmitt C; Goldwirt L; Pelton K; Haidar S; Levasseur C; Guehennec J; Knoff D; Labussière M; Marie Y; Ligon AH; Mokhtari K; Hoang-Xuan K; Sanson M; Alexander BM; Wen PY; Delattre JY; Ligon KL; Idbaih A
Clin Cancer Res; 2016 Mar; 22(5):1185-96. PubMed ID: 26482041
[TBL] [Abstract][Full Text] [Related]
10. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.
Stommel JM; Wahl GM
Cell Cycle; 2005 Mar; 4(3):411-7. PubMed ID: 15684615
[TBL] [Abstract][Full Text] [Related]
11. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
12. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
13. Synergistic tumor suppression by coexpression of FUS1 and p53 is associated with down-regulation of murine double minute-2 and activation of the apoptotic protease-activating factor 1-dependent apoptotic pathway in human non-small cell lung cancer cells.
Deng WG; Kawashima H; Wu G; Jayachandran G; Xu K; Minna JD; Roth JA; Ji L
Cancer Res; 2007 Jan; 67(2):709-17. PubMed ID: 17234782
[TBL] [Abstract][Full Text] [Related]
14. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
15. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
16. RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction.
Gao K; Wang C; Jin X; Xiao J; Zhang E; Yang X; Wang D; Huang H; Yu L; Zhang P
Cancer Lett; 2016 May; 375(1):133-141. PubMed ID: 26926424
[TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
18. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]